Navigation Links
Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform
Date:1/24/2008

s patient positioning for more rapid, effective, and comfortable treatments.

"Novalis Tx has the dose delivery rate, advanced imaging, and high definition beam shaping capability needed to offer faster, more precise, more comfortable radiosurgical procedures for our patients," said Fang-Fang Yin, Ph. D., professor and director of radiation physics at Duke University School of Medicine, which is completing the installation of a Novalis Tx.

Unlike other radiosurgical devices, Novalis Tx allows multiple beam energies from 6 to 20 million electron volts for treating deep-seated tumors and sparing surrounding healthy tissue more effectively. Clinics can treat twice the number of patients per day than with any other stereotactic radiosurgery system on the market. "The speed coupled with the precise beam shaping and advanced imaging capabilities make the most advanced radiosurgical treatments more affordable for hospitals and their patients," adds Dow Wilson.

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing

comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,400 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit http://www.varian.com/.

About BrainLAB

BrainLAB develops, manufactures and markets software-driv
'/>"/>

SOURCE Varian Medical Systems, Inc.; BrainLAB AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cranberry Could Juice Up Ovarian Cancer Treatment
2. New Ovarian Cancer Drug Trial Under Way
3. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
4. Pelvic Exams Can Help Spot Ovarian Cancer
5. Study fuels debate over whether exercise and body size influence ovarian cancer risk
6. Experimental drug boosts survival in recurrent ovarian cancer
7. New Ovarian Cancer Biomarker Research Act Introduced
8. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
9. More Fiber, Less Fat Help Prevent Ovarian Cancer
10. Media availability: low-fat dietary pattern may lower risk of ovarian cancer
11. The Silent Killer, Ovarian Cancer on Your Cancer Today (TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... in a phase 1/2 clinical trial that it ... patients newly diagnosed with multiple myeloma, a cancer of ... Dana-Farber Cancer Institute. , Partial responses or better were ... the drug combination in the multi-center study, with 74 ... the phase 2 population, reports Paul G. Richardson, MD, ...
(Date:12/5/2009)... myeloproliferative disorders are serious and often deadly blood ... Meeting of the American Society of Hematology introduces ... for patients suffering from acute promyelocytic leukemia, chronic ... that are based on a better understanding of ...
(Date:12/5/2009)... campaign is a collaborative effort by the National ... of North America (MANA), Citizens for Midwifery (CfM), ... Registry of Midwives (NARM), and the Midwifery Education ... the efforts of The MAMA Campaign to secure ...
(Date:12/4/2009)... Medithrive, Inc. has won the Patient,s Choice Award ... by popular vote conducted by the online website, ... SF Bay community has selected Medithrive as the preeminent ... rapid rise and popularity of Medithrive confirms the obvious: ...
(Date:12/4/2009)... Editorial Advisory and Securities Review Committee of BetterInvesting Magazine ... AGN ) as its February 2010 "Stock to Study" and ... as its February 2010 "Undervalued Stock" for investors, informational and ... opportunities involving its flagship drug Botox and other products as ...
Breaking Medicine News(10 mins):Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
... Federal funding for pain research is declining sharply, more than 9 ... in The Journal of Pain . Pain research, as ... awarded by the National Institutes of Health (NIH), despite the high ... startling finding shows the government,s meager investment in pain research is ...
... to public health , , ... unveiled health reform recommendations to Congress that would strengthen ... chronic diseases that are causing medical costs to spiral. ... proposals, federally funded insurance programs would provide highly cost-effective ...
... Karmanos, Work It Out (DKWIO), a,dynamic 501(c)(3) not-for-profit program ... today announced that Tracey Secco has joined,DKWIO as Director ... ten years,of experience in public relations and program management ... organization,s life-changing message. , ...
... PURE Bioscience,(Nasdaq: PURE ), creators of ... for the fiscal quarter ended October,31, 2008 of $110,600 ... year. The Company reported a loss from operations ... current quarter compared with a,loss of $(1,008,700), or $(0.04) ...
... agency officials warn , , THURSDAY, Dec. 11 (HealthDay News) ... by a U.S. Food and Drug Administration expert panel as ... these drugs has been going on for several years, with ... these drugs for anyone under 17. , One expert thinks ...
... First health insurer in Pennsylvania to open store in Mechanicsburg,s ... , CAMP HILL, Pa., Dec. 11 As ... on their own and small business owners look for health ... be the first health insurer in the state to open ...
Other Medicine News:Health News:Study shows major pain research funding decline at NIH 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Danialle Karmanos' Work It Out Names Tracey Secco as Director of Operations 2Health News:PURE Bioscience Reports First Quarter Results 2Health News:PURE Bioscience Reports First Quarter Results 3Health News:PURE Bioscience Reports First Quarter Results 4Health News:PURE Bioscience Reports First Quarter Results 5Health News:PURE Bioscience Reports First Quarter Results 6Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:Highmark Blue Shield to Open 'Highmark Direct,' a Health Insurance Retail Store 2Health News:Highmark Blue Shield to Open 'Highmark Direct,' a Health Insurance Retail Store 3
(Date:12/4/2009)... Dec. 4 Bayer Diabetes Care today announced the three ... Contest." Nick Jonas, of the Jonas Brothers, selected the winning ... country. The grand prize is an in-person meeting today with ... diabetes like Nick, are: Caleb, age 6, from Danbury, CT, ...
(Date:12/3/2009)... NEW YORK, Dec. 3 Guidepoint Global, LLC , ... their Sleep Apnea Tracker, a monthly longitudinal data release that ... Sleep Apnea market. ,, The Sleep Apnea Tracker captures ... sold in the United States from 15 different equipment providers ...
(Date:12/3/2009)... Chairman and CEO of The Quigley Corporation, (Nasdaq: ... Company has completed its evaluation of its opportunities to ... that it is in its best interests to focus ... but are not limited to its Cold-EEZE® and Kids-EEZE® ...
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Arcadian Health Plans Expand Their Medicare Health Plan Offerings and Enter Four New States 58975 1Arcadian Health Plans Expand Their Medicare Health Plan Offerings and Enter Four New States 58975 2The Pittsburgh Life Sciences Greenhouse Adds Life Sciences Veterans to Executive Program 14375 1The Pittsburgh Life Sciences Greenhouse Adds Life Sciences Veterans to Executive Program 14375 2Burn Rate in Kids Has Dropped But Still Causes Concern 58973 1Burn Rate in Kids Has Dropped But Still Causes Concern 58973 2Burn Rate in Kids Has Dropped But Still Causes Concern 58973 3
... 2007 - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical ... of novel drugs for the,treatment of metabolic ... targeting the liver and liver pathways, announced,today ... Endocrine Society's,89th Annual Meeting in Toronto, Canada., ...
... Results show risk of heart attack,comparable to two widely used ... LONDON , June 6, 2007 - A ... real-world,setting was published today. This study shows that the incidence ... revascularization for patients on Avandia is the,same as ...
Other Medicine Technology:Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 2Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 3Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 4Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
Inquire...
Inquire...
Bench Top Class I Containment Cabinet Personnel Protection...
Class II Type B1 Biological Safety Cabinet...
Medicine Products: